The US Presidential administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price of drugs in the US to the lowest price in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal government. In addition, the administration is pursuing traditional regulatory pathways to impose drug pricing policies, although proposed regulations have not yet been published. These policies may have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for any product candidate we commercialize.
All entries for: Atea Pharmaceuticals
March 6, 2025
Atea Pharmaceuticals
Layoffs
Bston, MA
51-200 employees
25% reduction in workforce.
Disease Area: Antiviral, Rare Diseases
Drug Type: Biologic, Small Molecule
November 8, 2023
Atea Pharmaceuticals
Negative Outlook
Bston, MA
51-200 employees
“We expect that additional US federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the US federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.”
Disease Area: Antiviral
Drug Type: Small Molecule
August 5, 2023
Atea Pharmaceuticals
Negative Outlook
Bston, MA
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
May 5, 2023
Atea Pharmaceuticals
Negative Outlook
Bston, MA
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
November 7, 2022
Atea Pharmaceuticals
Negative Outlook
Bston, MA
51-200 employees
Likely Signigifant: “Most significantly, on August 16, 2022, President Biden signed the IRA into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010… For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.”
Disease Area: Antiviral
Drug Type: Small Molecule